Pharma BD Deal Intelligence
Takeda exercised its 2017 option to acquire UK-based GammaDelta Therapeutics, gaining its allogeneic Vdelta1 gamma-delta T-cell platforms (blood- and tissue-derived) plus early-stage cell therapy programs for solid tumors. Financial terms were undisclosed (estimated ~$350M based on the prior option/payment structure). POST-CLOSE OUTCOME: on October 1, 2025 Takeda announced it would discontinue its cell therapy research as part of a strategic portfolio prioritization, recognizing an impairment loss of approximately JPY 58.0 billion primarily related to intangible assets associated with the gamma-delta T-cell therapy platform acquired in this deal. Takeda had no active cell therapy clinical trials at that point and said it would seek an external partner for the platform — effectively a write-down and wind-down of the acquired program roughly four years after the buyout.